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Abstract: Influenza vaccination often results in a large percentage of low responders, especially
in high-risk groups. As a first line of defense, natural killer (NK) cells play a crucial role in
the fight against infections. However, their implication with regard to vaccine responsiveness is
insufficiently assessed. Therefore, this study aimed at the validation of essential NK cell features
potentially associated with differential vaccine responsiveness with a special focus on NKG2C- and/or
CD57-expressing NK cells considered to harbor memory-like functions. To this end, 16 healthy
volunteers were vaccinated with an adjuvanted pandemic influenza vaccine. Vaccine responders
and low responders were classified according to their hemagglutination inhibition antibody titers.
A majority of responders displayed enhanced frequencies of NKG2C-expressing NK cells 7- or
14-days post-vaccination as compared to low responders, whereas the expression of CD57 was not
differentially modulated. The NK cell cytotoxic potential was found to be confined to CD56dimCD16+
NKG2C-expressing NK cells in the responders but not in the low responders, which was further
confirmed by stochastic neighbor embedding analysis. The presented study is the first of its kind
that ascribes CD56dimCD16+ NKG2C-expressing NK cells a crucial role in biasing adaptive immune
responses upon influenza vaccination and suggests NKG2C as a potential biomarker in predicting
pandemic influenza vaccine responsiveness.
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1. Introduction
Acute respiratory infections caused by the influenza virus are one of the major public health
problems leading to high mortality rates worldwide, and consequently, to a large societal economic
burden [1]. Occasionally, a novel virus arises, leading to worldwide spread and a pandemic. In the
last decade, a number of pandemic influenza vaccines have received marketing authorization [2].
An increase in hemagglutination inhibition (HAI) antibody titer is commonly used to measure the
response to the vaccine. However, antibody responses may be restricted in high-risk groups (i.e.,
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the very young and the elderly, individuals with co-morbidities), resulting in a large percentage of low
responders [3,4].
The generation of protective immunity requires the interplay between innate and adaptive
immune cells. NK cells are described as crucial innate immune cells in the fight against influenza
infections [5]. Recent findings in NK cell biology provide further evidence on specific functional
features of NK cells, which highlight a formerly underestimated role during infection. Several studies
revealed unexpected NK cell characteristics, like their continuous differentiation process and the
impact of the education status on the magnitude of NK cell functionality [6–9]. Likewise, it was
discovered that NK cells display adaptive immune features similar to T cells, including the generation
of memory-like NK cells [10,11]. Several reports highlighted the occurrence of murine memory-like
NK cells by (i) hapten-induced contact hypersensitivity, (ii) murine cytomegalovirus infection (MCMV)
and (iii) cytokine stimulation [12–15]. Human memory-like NK cells were first described in vivo as a
unique subset of NK cells expressing CD57 and NKG2C detected in a cohort of individuals infected
with the human cytomegalovirus (HCMV) [16–18]. Subsequently, it was also demonstrated that
human memory-like NK cells, characterized by the expression of NKG2C, could be induced in vitro
by cytokine stimulation [19,20]. The CD94-NKG2C activating NK cell receptor binds to HLA-E and
acts via the ITAM-bearing DAP12 signaling pathway [21]. CD57 is mainly expressed by terminally
differentiated NK cells, which are suggested to have undergone clonal expansion following infection.
CD57+ NK cells are described to harbor a lower proliferative capacity and to be less cytotoxic in
response to cytokine stimulation, but show higher CD16-induced cytotoxicity [22].
Next to their newly discovered functional features, NK cells are well known to interact directly
and indirectly with adaptive immune cells. Thus, it can be hypothesized that NK cells might be
considered as relevant players in the initiation of adaptive immunity following influenza vaccination.
Supporting evidence comes from a recent study, in which NK cell responsiveness following influenza
vaccination was investigated. The results of this study demonstrated that NK cells with an intracellular
immune memory, characterized by enhanced IFNγ secretion following antigen-specific re-stimulation,
are generated following vaccination [23]. These NK cells displayed an increased internalization of
the NKp46 receptor, which is known to interact with the influenza surface protein hemagglutinin
(HA). However, despite this fragmentary evidence, there is still a considerable paucity of knowledge
in this field. In this regard, NK cell subsets expressing CD57 and NKG2C have yet to be addressed.
Thus, in the present study, the impact of the H1N1 vaccination on phenotypic and functional changes
of NK cells expressing CD57 and NKG2C and their reciprocal influence on the vaccination efficacy
was investigated.
2. Materials and Methods
2.1. Study Design
Sixteen healthy volunteers (health care workers (HCWs)) were vaccinated with the pandemic
influenza vaccine Pandemrix® (split virion, inactivated; A/California/07/2009 (H1N1)v-like strain
(X-179A), GlaxoSmithKline, Brentford, UK), adjuvanted with AS03 as part of a large clinical trial.
Fourteen of the participants were female and two were male (one normal and one low-responder),
and they were born between 1951 and 1987 with a median birth year of 1974 and 1969 for normal-
and low-responders, respectively. Other than three participants (normal responders), all participants
received previous seasonal influenza vaccines. All participants provided written informed consent
before inclusion in the study, which had ethical (Regional Committee for Medical Research Ethics
(ethical approval number is 2009/1224, issued by REC west), Western Norway (REK Vest)) and
regulatory (Norwegian Medicines Agency) approval and is registered at the National Institute for
Health Database Clinical trials.gov (NCT01003288). Human subject rights were protected during the
trial and the data analysis. Blood (clotted and Cell Preparation Tubes (CPTs)) was collected prior and
7-, 14-, 21- and 180-days post-vaccination [24]. Peripheral blood mononuclear cells (PBMCs) were
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isolated from CPT tubes according to the manufacturer’s instructions and cryo-preserved in 90% fetal
bovine serum (FBS)/10% dimethyl sulfoxide (DMSO) until further analysis.
2.2. Humoral Immune Responses
The HAI titers in serum samples pre-vaccination and 7-, 14-, 21-, 90- and 180-days post-vaccination
were determined by a HAI assay using the X179A virus. The assay was performed with 0.7% turkey
red blood cells, as described previously [24]. The titers analyzed at days 0 and 90 were used to define
responders and low responders. Vaccinees with a 4-fold seroconversion or a titer increase >40 were
considered as responders. Human cytomegalovirus (CMV)-specific IgG antibodies were assessed
using the Alinity i instrument (Abbott).
2.3. Cellular Immune Responses
PBMCs were thawed and 1 × 106 to 4 × 106 cells/sample were re-stimulated for 16 h in complete
RPMI 1640 (Gibco, supplemented with 10% FCS, 5% Penicillin/Streptomycin and 5% Glutamine)
containing the vaccine formulation with a final concentration of 4 µg hemagglutinin (HA)/mL split
virus vaccine (kindly provided by GlaxoSmithKline, Belgium). Unstimulated samples were incubated
for the same time in complete RPMI without the vaccine formulation. Brefeldin A and monensin were
added to all samples after 5 h of incubation. Cells were collected and stained for flow cytometric
analysis. Surface marker staining was performed for 20 min at 4 ◦C. The following antibodies were used
diluted in PBS: CD56 (PE-Cy7, clone B159, BD, Franklin Lakes, NJ, USA), CD3 (V450, clone UCHT1,
BD), CD14 (Pacific Blue, clone M5E2, BD), CD19 (V450, clone HIB19, BD Horizon), CD16 (APC-H7,
clone 3G8, BD Pharmingen), NKG2C (PE, clone 134591, R&D Systems, Minneapolis, MN, USA),
CD57 (APC, clone HCD57, BioLegend, San Diego, CA, USA), Live/Dead (Fixable Blue, Invitrogen,
Carlsbad, CA, USA). The expression of CD107a was used as a correlate of degranulation. To this
end, the anti-CD107a antibody (PE-Cy5, clone eBioH4A3, eBioscience, San Diego, CA, USA) was
added to the culture. The secretion of IFNγ (Alexa Fluor 700, clone B27, BioLegend) was detected by
intracellular staining using Cytofix/Cytoperm solution (BD Biosciences). Samples were acquired at a
BD Fortessa flow cytometer and analyzed using FlowJo (FlowJo, LLC, Ashland, OR, USA). Unstained,
single stained (one antibody/sample) as well as fluorescence-minus-one (FMO) samples were used as
controls for the acquisition as well as the subsequent analysis. Statistical differences were determined
by the GraphPad Prism software.
2.4. Stochastic Neighbor Embedding (SNE) Analysis
Flow cytometry data of responders and low responders derived pre- and 7-days post-vaccination
were imported into FlowJo (version 9) and compensation channel values were extracted for the
following parameters: CD56, CD16, NKG2C, CD57, CD107a and IFNγ. Up to 10,000 values were
extracted per vaccinee and time point and then pooled for responders and low responders. By using
the R package “tsne”, a t-distributed SNE analysis using Barnes–Hut implementation was performed
and the resulting data were plotted with intensities for the depicted markers (RStudio version 3.2.1,
RStudio, Inc., Boston, MA, USA), as described earlier [25,26].
2.5. Statistical Analysis
GraphPad Prism (version 6.0 for Windows, GraphPad Software, La Jolla, CA, USA) was used
for the statistical assessment (unpaired low-parametric Mann–Whitney or Kruskal–Wallis test and
Spearman correlation). Values of p ≤ 0.05 were considered significant.
Vaccines 2020, 8, 281 4 of 18
3. Results
3.1. Influenza Vaccination Leads to Enhanced Frequencies of NKG2C-Expressing NK Cells
NK cells are characterized by the intensity of CD56 expression and the co-expression of CD16 and
can be thereby divided into different functional subsets (see gating strategy, Figure S1). The impact of
pandemic vaccination on the distribution of blood NK cell subsets was assessed by flow cytometry
at various time points. A slightly reduced frequency of total NK cells in vaccinated individuals was
observed during the first 14 days after vaccination (≈6% at day 0 to ≈5.4% at day 7 and 4.5% at day
14) (Figure 1a). The marginally diminished frequency remained relatively stable over the observation
period until day 180 post-vaccination (≈5% at day 21 and ≈4.8% at day 180). The division of NK
cells into primarily cytokine secreting CD56bright and highly cytotoxic CD56dim subsets revealed a
decrease in the CD56dim NK cell frequencies, especially of CD56dimCD16+ cells (≈48% at day 0 to ≈34%
at day 7), whereas CD56bright NK cell frequencies were not affected (Figure 1b). These data suggest
that vaccination-induced modulation mainly affects CD56dimCD16+ NK cells, which are described
to hold a higher cytotoxic but lower cytokine secreting capability as compared to CD56bright NK
cells [27]. Human memory-like NK cells based either on the expression of CD57 and NKG2C or
NKG2C alone were recently described to exert amplified recall responses upon CMV infection or to
be induced after cytokine stimulation (IL-12, IL-15 and IL-18), respectively [13,17,20]. The analysis
of CD56dimCD16+ NK cells with regard to CD57 and NKG2C expression after pandemic vaccination
revealed that the changes in NK cell frequencies were mainly restricted to the NKG2C-expressing
subsets. Increased frequencies of both CD57−NKG2C+ (from ≈2% at day 0–9% at day 7 and ≈8% at
day 14) and CD57+NKG2C+ NK cell subsets (from ≈1% at day 0–4% at day 7 and ≈7% at day 14)
were detected at days 7 and 14 post-vaccination (orange and red) in samples derived from 8 out
of 10 vaccine responders (marked with an arrow, Figure 1c). The most striking differences were
observed at day 7 and 14 post-vaccination, with significantly elevated levels of both CD57−NKG2C+
and CD57+NKG2C+ NK cells, whereas the frequency of CD57+NKG2C− NK cells was not affected
(Figure 1d). Within the NKG2C-expressing subsets, high ratios comparing post- and pre-vaccination
values were detected (≥1.5, red data points) while the CD57+NKG2C− NK cell subset showed ratios > 1
(blue data points), but not ≥1.5. The analysis of NK cells either expressing NKG2C or CD57 confirmed
the increased frequency of NKG2C but not CD57 expression (Figure 1e). The data suggest that
adjuvanted pandemic vaccination induces changes in the subset of NKG2C-expressing NK cells, which
in turn can be potentially involved in determining the outcome of vaccination. While the frequency of
NKG2C-expressing NK cells is described to be connected with CMV sero-positivity, no such correlation
was found here (Figure S2a) [16,17]. Furthermore, no differences between the mean CMV titer of low
and normal responders was observed (Figure S2b). The correlation analysis of the CMV titer and the
fold change of the HAI titer or the age of the participants also did not yield any significant relation
(Figure S2c). Likewise, the fold change of the HAI titer did not correlate with the age of the vaccinees
(Figure S2d). However, in normal but not in low responders, the frequency of NKG2C+CD57+ NK
cells at day 7 post-vaccination showed a significant negative correlation with the age of the vaccinees
(Figure S2e). These findings highlight that the hypothesized relation between NKG2C+ NK cells and
the vaccination outcome is not dependent on the CMV sero-status, thus supporting publications stating
that CMV infections do not affect influenza vaccine efficacy [28].
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Figure 1. Influenza vaccination affects the frequency of NKG2C-expressing natural killer (NK) cells. 
Peripheral blood mononuclear cells (PBMCs) isolated from vaccinated individuals prior to 
vaccination and at the indicated time points post-vaccination (dpv = days post-vaccination) were 
stained for the surface markers CD56, CD3, CD16, NKG2C and CD57. (a) Frequencies of total 
CD3−CD56+ NK cells and (b) of CD3-CD56bright, CD3−CD56dim and CD3−CD56dimCD16+ NK cell 
subpopulations. Diagrams show the connected column mean with 95% confidence interval. (c) 
Frequencies of NK cell populations characterized by the expression of CD57 and NKG2C. Columns 
represent individual data points. (d) CD57- and NKG2C-expressing CD56dimCD16+ subpopulations 
depicted as the ratio of cell frequencies detected at the indicated time points post-vaccination and the 
frequencies detected prior vaccination (day 0). Diagrams are depicted as scatter plots with bars of 
individual assigned data points. (e) CD56dimCD16+NKG2C+ and CD56dimCD16+CD57+ NK cells 
displayed as frequencies and as the ratio to the day before vaccination. Columns represent individual 
data points; diagrams are depicted as scatter plots with bars of individual assigned data points. 
Arrows indicate donors with vaccine-induced immunological changes. Asterisks denote significant 
values as calculated by unpaired and non-parametric Kruskal–Wallis test. * p ≤ 0.05. Letters in panels 
(d, e) indicate single responders. 
Figure 1. Influenza vaccination affects the frequency of NKG2C-expressing natural killer (NK) cells.
Peripheral blood mononuclear cells (PBMCs) isolated from vaccinated individuals prior to vaccination
and at the indicated time points post-vaccination (dpv = days post-vaccination) were stained for the
surface markers CD56, CD3, CD16, NKG2C and CD57. (a) Frequencies of total CD3−CD56+ NK
cells and (b) of CD3−CD56bright, CD3−CD56dim and CD3−CD56dimCD16+ NK cell subpopulations.
Diagrams show the connected column mean with 95% confidence interval. (c) Frequencies of NK cell
populations characterized by the expression of CD57 and NKG2C. Columns represent individual data
points. (d) CD57- and NKG2C-expressing CD56dimCD16+ subpopulations depicted as the ratio of
cell frequencies detected at the indicated time points post-vaccination and the frequencies detected
prior vaccination (day 0). Diagrams are depicted as scatter plots with bars of individual assigned data
points. (e) CD56dimCD16+NKG2C+ and CD56dimCD16+CD57+ NK cells displayed as frequencies and
as the ratio to the day before vaccination. Columns represent individual data points; diagrams are
depicted as scatter plots with bars of individual assigned data points. Arrows indicate donors with
vaccine-induced immunological changes. Asterisks denote significant values as calculated by unpaire
and non-parametric Kruskal–Wallis test. * p ≤ 0.05. Letters in panels (d, e) in icate sin le responders.
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3.2. NK Cells of Influenza Vaccination Responders and Low Responders Display Differences in NKG2C and
CD57 Expression
The inefficacy of influenza vaccines, characterized by the varying occurrence of low responders, is
a persisting problem. To classify normal and low responders following pandemic vaccination, the
HAI titer of each vaccinee was evaluated at days 0 and 90 post-vaccination (Figure S3). The total
frequencies of NK cells derived from normal and low responders were compared, as well as the
expression of CD57 and NKG2C. Reduced frequencies of CD56dimCD16+ NK cells were observed
in both response groups at 7-days post-vaccination, as compared to day 0. However, the decrease
was less profound in normal responders (≈30% reduction for responders and ≈46% reduction for low
responders) (Figure 2a). These findings were consistent with the assessed ratios of NK cell frequencies
(day 7/day 0). The assessment of CD57 expression prior to vaccination demonstrated differences in its
basal expression by NK cells derived from normal and low responders (day 0). However, the ratio
of CD56dimCD16+CD57+ NK cell frequencies (day 7/day 0) revealed no vaccine-induced effect on
CD57 expression (ratios ≈1 for both responders and low responders (Figure 2b). The analysis of
CD56dimCD16+NKG2C+ NK cells revealed an increased frequency at day 7 post-vaccination in normal
responders that was not observed in low responders (Figure 2c). The ratio of CD56dimCD16+NKG2C+
NK cell frequencies (day 7/day 0) supports this finding by displaying a higher ratio for normal
responders (≈6) as compared to low responders (≈1). This difference is further highlighted by ratios
mainly ≥1.5 (red dots) detected for NKG2C-expression by CD16+ NK cells derived from normal
responders. This indicates that responders show increased frequencies of NKG2C+ expression at day 7
post-vaccination as compared to day 0, whereas NKG2C expression in low responders remains largely
unaffected. To address whether the observed increased frequency of NKG2C+ NK cells is due to the
specific antigen (HA) re-stimulation, an individual analysis of single donors was performed. These data
revealed that a significant number of responders displayed an HA-induced surface expression of
NKG2C that was not observed in the group of low responders (Figure 2d, ratio (HA/unstimulated
(NS)) >1 = blue, ≥1.5 = red). Interestingly, the individuals responding to HA re-stimulation with
enhanced expression of NKG2C already displayed a higher basal expression. With regard to the
HA-induced surface expression of CD57, neither vaccine responders nor low responders displayed a
strong modulation, as indicated by ratios (HA/unstimulated) >1 but not≥1.5 (Figure 2e). These findings
suggest that NKG2C-expressing NK cells bias vaccine responsiveness and might serve as a determinant
of responsiveness towards influenza vaccination.
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Figure 2. Phenotypic analysis of NK cells derived from normal and low responders to the pandemic 
influenza vaccination. Flow cytometric analysis of frozen PBMCs isolated from vaccinated 
individuals classified into normal responders (black dots) and low responders (white dots; a-c). 
Frequencies and ratios of (a) CD56dimCD16+, (b) CD56dimCD16+CD57+ and (c) CD56dimCD16+NKG2C+ 
NK cells. Diagrams are depicted as scatter dot plots indicating the mean by a horizontal line. Ratios 
were derived from cell frequencies detected at day 7 post-vaccination and the frequencies detected 
prior to vaccination (day 0) depicted as scatter plots with bars. Ratios of unstimulated (NS) and HA-
re-stimulated (HA) (d) CD56dimCD16+NKG2C+ and (e) CD56dimCD16+CD57+ NK cells derived from 
normal and low responders. Blue dots depict ratios >1 and red dots depict values ≥ 1.5. 
3.3. CD107a Expression is Confined to CD56dimCD16+NKG2C-Expressing NK Cells in Responders but not 
in Low Responders 
To dissect whether, in addition to the phenotypic alterations, the functionality of CD56dim NK 
cells in normal and low responders also differs, CD16 expression, CD107a expression and IFNγ 
secretion were addressed ex vivo. Independently of the responsiveness to vaccination, differences in 
the functionality of CD16- and CD16+ NK cells within the CD56dim subset were detected (Figure 3a,b). 
The analysis of the NK cell degranulation capacity revealed that within the group of responders, 
CD56dimCD16− NK cells showed no changes in the frequency of CD107a-expressing cells after 
vaccination (Figure 3a). In contrast, CD56dimCD16+ NK cells derived from responders exhibited an 
enhanced expression of CD107a peaking at day 7 post-vaccination. Low responders showed similar 
functional differences between CD56dimCD16- and CD16+ NK cells (Figure 3a). CD56dimCD16+ NK cells 
showed a higher frequency of CD107a-expressing cells at day 7 post-vaccination as compared to day 
0. The comparison of normal and low responders further revealed that responders harbor a lower 
frequency of CD56dimCD16+CD107a+ NK cells at day 7 post-vaccination (≈4%) as compared to low 
responders (≈12%) (Figure 3a). 
Figure 2. Phenotypic analysis of NK cells derived fro r l and low responders to the pandemic
influenza vaccination. Flow cytometric analysis of frozen PBMCs isolated from vaccinated indivi uals
classifie into normal r sponders (black d ts) and low responders ( hite dots; a-c). Frequencies and
ratios of (a) CD56dimCD16+, (b) CD56dimCD16+ 57+ and (c) CD56 imCD16+NKG2C+ NK cells.
Diagrams are depicted as scatter dot plots indicating the mean by a horizontal line. Ratios were derived
from cell frequencies detected at day 7 post-vaccination and the frequencies detected prior to vaccination
(day 0) depicted as scatter plots with bars. Ratios of unstimulated (NS) and HA-re-stimulated (HA)
(d) CD56dimCD16+NKG2C+ and (e) CD56dimCD16+CD57+ NK cells derived from normal and low
responders. Blue dots depict ratios >1 and red dots depict values ≥ 1.5.
3.3. CD107a Expression Is Confined to CD56dimCD16+NKG2C-Expressing NK Cells in Responders but Not in
Low Responders
To dissect whether, in addition to the phenotypic alterations, the functionality of CD56dim NK
cells in normal and low responders also differs, CD16 expression, CD107a expression and IFNγ
secretion were addressed ex vivo. Independently of the responsiveness to vaccination, differences in
the functio lity of CD16− and CD16+ NK cells within the CD56dim subset were detected (Figure 3a,b).
The analysis of the K cell degranulation capacity revealed that within the group of responders,
CD56dimCD16− NK cells showed no changes in the frequency of CD107a-expressing cells after
vaccination (Figure 3a). In contrast, CD56dimCD16+ NK cells derived from responders exhibited an
enhanced expression of CD107a peaking at day 7 post-vaccination. Low responders showed similar
functional differences between CD56dimCD16− and CD16+ NK cells (Figure 3a). CD56dimCD16+ NK
cells showed a higher frequency of CD107a-expressing cells at day 7 post-vaccination as compared to
day 0. The comparison of normal and low responders further revealed that responders harbor a lower
frequency of CD56dimCD16+CD107a+ NK cells at day 7 post-vaccination (≈4%) as compared to low
responders (≈12%) (Figure 3a).
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Figure 3. Functional differences characterize NK cells isolated from normal and low responders. 
Functional flow cytometric analysis of frozen PBMCs isolated from vaccinated individuals classified 
into normal and low responders. Frequencies of (a) CD107a+CD56dim and (b) IFNγ+CD56dim NK cells 
with regard to CD16 expression (CD16− white/CD16+ black). Ratio of CD107a-expressing (c) 
CD57−NKG2C+, (d) CD57+NKG2C+ and (e) CD57+NKG2C− CD56dimCD16+ NK cells isolated from 
responders and non-responders on the indicated days post- and pre-vaccination (day 0) depicted as 
scatter plots with bars indicating the mean with 95% confidence interval. (f) Frequency of 
CD56dimCD16+ NK cells expressing CD107a (red solid), NKG2C+CD57− (black solid), NKG2C+CD57+ 
(green), NKG2C−CD57+ (black dashed) shown for individual responders and (g) non-responders. 
Asterisks denote significant values as calculated by unpaired and non-parametric Mann–Whitney 
test. * p ≤ 0.05, ** p ≤ 0.01. 
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expressing CD107a (red solid), NKG2 +CD57− (black solid), NKG2C+CD57+ (green), NKG2C− 57+
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The analysis of IFNγ-expressing CD56dim NK cell subsets derived from responders revealed that
vaccination differentially impacts CD16− and CD16+ NK cells only at day 7 post-vaccination as compared
to all other investigated time points (day 0, 14, 21 and 180 post-vaccination) (Figure 3b). Normal
responders harbored a lower frequency of CD56dimCD16+IFNγ+ NK cells at day 7 post-vaccination
(≈5%) as compared to low responders (≈17%) (Figure 3b).
An investigation of the NK cell functionality depending on CD57 and NKG2C expression revealed
elevated levels in the expression of CD107a in normal and low responders. Interestingly, within the
subset of CD57−NKG2C+ NK cells, low responders showed a 22-fold higher CD107a expression
as compared to responders at day 7 (Figure 3c). Within the subset of CD57+NKG2C+ NK cells,
the comparison of normal and low responders showed less profound differences (3.5 fold increase)
(Figure 3d). CD107a expression within the CD57+NKG2C− NK cell subset showed marginal changes in
responders (≈1.5-fold), whereas low responders displayed a six-fold increase at day 7 post-vaccination
(Figure 3e).
The analysis of individual responders highlights distinct, donor specific differences within the
groups of normal and low responders. Thus, five out of 10 responders (R1, R2, R5, R8, and R9) showed
enhanced frequencies of both NKG2C-expressing NK cell subsets at day 7 or 14 after vaccination as
compared to day 0 (Figure 3f). This increase appears to be associated with an elevated level of CD107a
as well as a decreased frequency of CD57+NKG2C− NK cells. Interestingly, the CD57+NKG2C+ subset
seems to be strongly associated with the expression of CD107a as compared to the CD57-NKG2C+ subset
in six out of 10 normal responders (Figure 3f). On the other hand, five out of six low responders (NR1,
NR2, NR3, NR5, and NR6) did not show this correlation. These results suggest that the functionality of
NK cells derived from responders is confined within both NKG2C-expressing subpopulations.
3.4. Elevated NKG2C-Expression Correlates with a Higher Expression of CD107a
A correlation analysis of the frequency of CD56dimCD16+CD57+NKG2C+ NK cells on day 0/7
post-vaccination and the degranulation capacity of CD56dimCD16+ NK cells (frequency of CD107a+ NK
cells) on day 7 revealed a substantial positive correlation for NK cells derived from normal responders
(Figure 4a). Within the group of low responders, no significant correlation between the frequency of
CD56dimCD16+CD57+NKG2C+ NK cells and their CD107a expression at days 0 or 7 post-vaccination
was found (Figure 4b). An SNE analysis confirmed that CD56dimCD16+ NK cells derived from normal
responders prior and 7-days post-vaccination overlap with regard to the expression of NKG2C and
CD107a as detected by flow cytometry. Interestingly, this overlap was not detected for low responders
(Figure 4c). The obtained data suggest that CD107a expression within the CD56dimCD16+NKG2C+
NK cell subset might represent an early correlate of vaccine responsiveness.
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4. Discussion
NK cells represent an innate immune cell population that acts as a first line of defense by killing
viral infected cells and regulating cells of the adaptive immune system by means of secreted cytokines.
This renders NK cells as promising immune players to be considered for the development of vaccination
strategies against viral pathogens. The few studies investigating NK cells following the vaccination of
healthy adults revealed their beneficial effect against a variety of pathogens. Enhanced frequencies of
IFNγ-secreting NK cells upon malaria vaccination were associated with antigen-specific IL-2 secretion
and considered as a marker for antigen-specific T cell activation [29]. Vaccination against the rabies
virus demonstrated a significant impact of NK cell activation for vaccine-induced effector as well as
recall responses [30]. Furthermore, reduced viral loads upon vaccination with live attenuated yellow
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fever vaccine correlated with enhanced NK cell functionality, such as activation and degranulation [31].
Influenza vaccines were reported to induce changes in NK cell receptor repertoires and to promote
increased IFNγ secretion [32]. A reduced CD16 expression by NK cells was also described in the
context of a robust influenza-specific IgG response [33]. However, there is a paucity of knowledge
concerning the potential implications of NK cells in responsiveness to influenza vaccines. To the best of
our knowledge, this is the first study aiming at the validation of phenotypic and functional differences
of NK cells isolated from vaccine responders and low responders.
The analysis of peripheral blood NK cell frequencies upon immunization with the adjuvanted
pandemic H1N1 vaccine revealed a slight decrease over time. The observed decrease might result
from activation and subsequent migration to secondary lymphoid organs. Interestingly, at day 7
post-vaccination, increased frequencies of CD56dimCD16+NKG2C+ NK cells were detected within the
group of vaccine responders as compared to low responders. The increased expression of NKG2C upon
influenza vaccination was observed regardless of CD57 expression. NKG2C-expressing NK cells were
demonstrated to respond in vitro to cytokine stimulation [20]. Beneficial implications for NKG2C+ NK
cells in natural infections with HIV, HBV, Hanta and Chikungunya viruses were recently shown by
other groups [34–36]. However, few studies addressed the effect of vaccination on NKG2C-expressing
NK cells. The vaccination of healthy volunteers with a low-adjuvanted split influenza vaccine or with
a low-adjuvanted dendritic cell-based HIV vaccine revealed no major changes in the frequency of
NKG2C- and/or CD57-expressing NK cells [23,37]. These findings might suggest that the observed
increase in NKG2C-expressing NK cells upon pandemic influenza vaccination is due to adjuvantation
with AS03. However, the immunization of macaques with a live attenuated SIV vaccine and a
subsequent challenge was found to result in elevated frequencies of NKG2C-expressing circulating
T cells in vaccinated but not unvaccinated animals [38]. Another study with SIV-infected rhesus
macaques demonstrated the NK cell-mediated killing of antigen-pulsed DCs in a NKG2C-dependent
manner [39].
The gain of CD57 expression is associated with immune cell maturation and senescence [21,40,41].
In the present study, responders displayed a higher basal level of CD57+ NK cells compared to
low responders. However, the influenza vaccination itself did not result in any further changes.
The functional analysis of CD56dimCD16+ NK cells at day 7 post-vaccination pointed to both responders
and low < responders displaying enhanced IFNγ secretion and CD107a expression. This is in agreement
with a previous study showing increased IFNγ-secretion following seasonal influenza vaccination [32].
The present work revealed that NK cells derived from responders secrete less IFNγ and show a
reduced degree of degranulation as compared to low responders. Recent reports describe that NK cells
activated by immunization or viral infections can lyse activated T cells, and thus prevent the efficient
formation of a memory T cell pool required for long-term protective immunity [42–44]. This might
explain, at least in part, the reduced humoral immune response defining low responders. Therefore,
an enhanced NK cell functionality might result in a decreased memory T cell pool, and thus a reduced
vaccine efficacy.
Taking into consideration the expression of CD57 and NKG2C, the analysis of the degranulation
capacity revealed a correlation between CD107a expression in CD57−NKG2C+ and CD57+NKG2C+ NK
cell populations and the overall responsiveness to vaccination. Recent studies described the generation
of highly degranulating and IFNγ-secreting NKG2C+ NK cells upon CD16 cross-linking or by the
activation of natural cytotoxicity receptors [36,45]. Furthermore, CD57+ NK cells are reported to exhibit
a high basal cytotoxic potential [41]. Thus, the observed high basal level of CD57+ NK cells in responders
might contribute to influenza vaccine responsiveness. In this regard, the significant correlation of
CD56dimCD16+CD57+NKG2C+ frequencies pre-vaccination with the NK cell degranulation capacity
found in responders but not for low responders suggests that the NK cell status at basal level and early
upon vaccination might contribute to the overall vaccine responsiveness. The tSNE analysis confirmed
the positive correlation and a two-dimensional overlap of degranulation and NKG2C-expressing
NK cells that was not observed for low responders. In murine studies, degranulating NK cells were
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described to harbor immune-regulatory functions as well as to imprint adaptive immune responses [42].
Thus, NK cell-mediated antiviral activity via cytotoxicity was shown to promote early CD8 T cell
responses [43]. Furthermore, NK cells can contribute to improved antigen-presentation by killing
infected cells, thereby resulting in antigen-specific CD4 T helper cell responses and subsequent
stimulation of humoral immunity [46]. Therefore, CD107a+NKG2C-expressing NK cells might bias
vaccine responsiveness. A seasonal influenza vaccine study revealed enhanced frequencies of CD107a
NK cells induced by increased IL-2 levels and immune complexes [47]. Interestingly, in the present
study, responders displayed enhanced numbers of IL-2 secreting T cells as compared to low responders.
Thus, the increased amount of IL-2 might affect the NK cell degranulating capacity (data not shown).
Although, CD56dimCD16+ NK cells displayed differences in the level of IFNγ secretion in
responders and low responders, no correlation to either CD57 or NKG2C expression was detected
(data not shown). A similar functional dichotomy of NKG2C+ NK cells was observed in patients
suffering from chronic HCV infection in which an altered phenotype defined by enhanced frequencies
of NKG2C+ NK cells was associated with enhanced expression of CD107a but not increased secretion
of IFNγ [48]. Thus, a differential activation of degranulating or cytokine-secreting NKG2C+ NK cells
might be similarly induced by the adjuvanted influenza vaccine.
Interestingly, human NKG2C-expressing NK cells are described to show memory-like features
(e.g., clonal expansion) and enhanced specific recall responses such as proliferation and cytokine
secretion [13,18,49,50]. Thus, the observed increased expression of NKG2C in responders might
suggest a vaccine-induced generation of an NK cell pool with memory-like features. A previous
influenza infection or immunization might have contributed to the formation of antigen-specific
NKG2C-expressing NK cells, which can rapidly be activated after vaccination. The increased expression
of NKG2C at days 7 and 14 post-vaccination in a few responders following HA re-stimulation supports
this hypothesis. In a murine model, the generation of influenza-specific memory-like NK cells
characterized by the expression of CXCR6 was reported [12]. It is known that the human receptor
NKp46 binds specifically to influenza HA on the surface of infected cells [51]. Recent studies described
NKp46-internalization as a distinct feature of influenza-specific memory-like NK cells [23]. In line
with the concept of memory-like NK cells, antigen-specific recall responses were also reported for
NK cells isolated from SIV-infected macaques, as well as in cells from human pleural fluid derived
from tuberculosis patients upon re-stimulation with the Bacillus Calmette-Guérin vaccine [39,52].
These findings support a crucial role of CD56dimCD16+NKG2C+ NK cells for determining the outcome
of vaccination. Interestingly, the phenotype of memory-like NK cell populations in humans is not
consistent in the different models investigated to date. For example, CMV-induced memory-like NK
cells express both NKG2C and CD57, whereas in vitro cytokine-induced memory-like NK cells are
defined by the expression of NKG2C, amongst other markers, but the lack of CD57 expression [16,19,20].
The enhanced basal frequencies of CD57+NKG2C+-expressing NK cells in CMV-positive individuals [53]
might raise concerns about whether our findings are due to an underlying chronic CMV infection.
However, the increased expression of NKG2C at days 7 and 14 ex vivo and upon HA re-stimulation
strongly argues for an influenza vaccination-induced effect. With regard to demographic information of
the participants, no correlation explaining a vaccine bias could be detected. Furthermore, it should be
noted that a small number of participants was involved in the presented study arm (n = 16). Additional,
more extensive studies will be needed to confirm the presented data and to consider including NK cell
targeting in future vaccination strategies.
The differentiation status of CD56dimCD16+ NK cells, defined by the expression of NKG2A,
KIR and CD57, dictates their functionality [7,8]. The efficacy of the yellow fever vaccination was
associated with a less differentiated NK cell phenotype defined by lack of CD57. However, it seems
that vaccination with an adjuvanted pandemic vaccine does not affect NK cell differentiation at the
analyzed time points (data not shown). This is consistent with another study, which investigated the
effect of a seasonal influenza vaccination on NK cell differentiation and functionality [32].
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Natural killer T (NKT) cells are described to bridge the innate and adaptive immune system by
expressing surface markers characteristic for NK as well as for T cells, e.g., CD3 and CD56. Although
in the murine system they were described to improve influenza-specific innate as well as adaptive
immune responses, their impact in the human system is insufficiently studied [54,55]. Activation
of NKT cells by the lipid antigen α-galactosylceramide or its analogs is discussed in the context of
novel vaccination strategies [56,57]. They are further known to directly impact NK cell functionality
via the secretion of activating (e.g., IFNγ and TNFα) as well as inhibitory cytokines (e.g., IL-4 and
IL-10). Therefore, assessing the specific impact of NKT cells in the course of influenza infection or
vaccination in future studies in the human system will help to further elucidate potential innate
immune mechanisms affecting vaccine responsiveness.
The vaccine formulation used in this study contains the oil-in-water emulsion-based adjuvant
system 03 (AS03). In accordance with earlier reports, the adjuvant contributes to enhanced antigen
loading and presentation by antigen-presenting cells (APCs) and the generation of chemokine and
cytokine gradients recruiting inflammatory cells to the site of injection [58,59]. NK cells are directly
activated by binding of influenza-induced ligands, e.g., on infected DCs, to NKG2D and NKp46
(recognizing the viral HA) [60]. These interactions, as well as HA-recognition by co-stimulating
molecules, such as 2B4 and NTB-A, lead to the elimination of infected cells by NK cell cytotoxicity [61].
Furthermore, the binding of CD16, expressed by NK cells, to the Fc region of surface-bound antibodies
against viral proteins leads to the activation of antibody-dependent cellular cytotoxicity mediated
by NK cell-derived granzyme B and perforin [62]. The AS03-enhanced antigen-presentation and
cytokine secretion, e.g., by DCs, macrophages, monocytes, and neutrophils might thereby indirectly
affect the phenotype of human NK cells and correspondingly increase their functionality. Nevertheless,
regardless of the specific formulation, the data presented here clearly demonstrated the impact of
vaccination on NK cell population composition and functionality, as well as the fact that changes in
NK cell phenotype and functionally correlate with vaccine responsiveness. Therefore, acquisition of
NKG2C might represent one potential early determinant to differentiate between responders and low
responders, as well as be a driving force to promote efficacious adaptive responses post-vaccination.
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